Abstract:ABSTRACT Throughout life, humans experience repeated exposure to viral antigens through infection and vaccination, resulting in the generation of diverse, antigen-specific antibody repertoires. A paramount feature of antibodies that enables their critical contributions in counteracting recurrent and novel pathogens, and consequently fostering their utility as valuable targets for therapeutic and vaccine development, is the exquisite specificity displayed against their target antigens. Yet, there is still limited understanding of the determinants of antibody-antigen specificity, particularly as a function of antibody sequence. In recent years, experimental characterization of antibody repertoires has led to novel insights into fundamental properties of antibody sequences but has been largely decoupled from at-scale antigen specificity analysis. Here, using the LIBRA-seq technology, we generated a large data set mapping antibody sequence to antigen specificity for thousands of B cells, by screening the repertoires of a set of healthy individuals against 20 viral antigens representing diverse pathogens of biomedical significance. Analysis uncovered virus-specific patterns in variable gene usage, gene pairing, somatic hypermutation, as well as the presence of convergent antiviral signatures across multiple individuals, including the presence of public antibody clonotypes. Notably, our results showed that, for B-cell receptors originating from different individuals but leveraging an identical combination of heavy and light chain variable genes, there is a specific CDRH3 identity threshold above which B cells appear to exclusively share the same antigen specificity. This finding provides a quantifiable measure of the relationship between antibody sequence and antigen specificity and further defines experimentally grounded criteria for defining public antibody clonality. IMPORTANCE The B-cell compartment of the humoral immune system plays a critical role in the generation of antibodies upon new and repeated pathogen exposure. This study provides an unprecedented level of detail on the molecular characteristics of antibody repertoires that are specific to each of the different target pathogens studied here and provides empirical evidence in support of a 70% CDRH3 amino acid identity threshold in pairs of B cells encoded by identical IGHV:IGL(K)V genes, as a means of defining public clonality and therefore predicting B-cell antigen specificity in different individuals. This is of exceptional importance when leveraging public clonality as a method to annotate B-cell receptor data otherwise lacking antigen specificity information. Understanding the fundamental rules of antibody-antigen interactions can lead to transformative new approaches for the development of antibody therapeutics and vaccines against current and emerging viruses.

Human antibody polyreactivity is governed primarily by the heavy-chain complementarity-determining regions

Biochemical and biophysical characterization of natural polyreactivity in antibodies

Biochemical patterns of antibody polyreactivity revealed through a bioinformatics-based analysis of CDR loops

Stimulation of Toll-Like Receptors profoundly influences the titer of polyreactive antibodies in the circulation

Protein language models enable prediction of polyreactivity of monospecific, bispecific, and heavy-chain-only antibodies

Learning the heterogeneous hypermutation landscape of immunoglobulins from high-throughput repertoire data

Co-optimization of therapeutic antibody affinity and specificity using machine learning models that generalize to novel mutational space

Learning the Language of Antibody Hypervariability

Restricted epitope specificity determined by variable region germline segment pairing in rodent antibody repertoires.

Large-scale data mining of four billion human antibody variable regions reveals convergence between therapeutic and natural antibodies that constrains search space for biologics drug discovery

Learned features of antibody-antigen binding affinity

Polyreactivity and polyspecificity in therapeutic antibody development: risk factors for failure in preclinical and clinical development campaigns

Machine learning optimization of candidate antibody yields highly diverse sub-nanomolar affinity antibody libraries

Predictability of antigen binding based on short motifs in the antibody CDRH3

Development of novel humanized VHH synthetic libraries based on physicochemical analyses

Sequence features of variable region determining physicochemical properties and polyreactivity of therapeutic antibodies

Local and global anatomy of antibody-protein antigen recognition

Antibody sequence determinants of viral antigen specificity

Cross‐reaction mediated by distinct key amino acid combinations in the complementary‐determining region (CDR) of a monoclonal antibody

Antibody humanization—the Influence of the antibody framework on the CDR-H3 loop ensemble in solution